八基诺林衍生物,克里奥基诺,是一种α-1 adrenoceptor对抗剂
Ashenafi H Betrie1, Alaa Abdul-Ridha2, Herodion Hartono3
1Translational Neurodegeneration Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia; Translational Cardiovascular and Renal Research Group, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.
Biochemical pharmacology
|February 26, 2024
概括
克里奥基诺,一种抗菌剂,在低度下起到竞争性α-1 adrenoceptor对手的作用,有助于血管松. 这种新的机制补充了其在血管光滑肌肉中已知的离子体效应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
- 分子生物学分子生物学
背景情况:
- 克里奥奎诺 (5-chloro-7-iodo-8-hydroxyquinoline) 是一种具有离子体和化剂特性的抗菌剂.
- 以前的研究表明,克里奥奎诺尔通过感觉神经,内皮和血管光滑肌肉引起血管松.
- 对克里奥奎诺和类似化合物的兴趣正在增长,用于治疗感染,神经退行和癌症.
研究的目的:
- 调查克里奥基诺尔对血管收缩性的新型作用机制.
- 为了确定克里奥奎诺是否作为α-1 (α1) 上腺素受体对手.
- 阐明克里奥基诺尔与α1上腺受体相互作用的结构基础.
主要方法:
- 在老鼠中腔动脉中进行的ex vivo功能性血管收缩测定.
- 药理技术和受体结合测试.
- 使用α1A和α1B上腺受体结构进行分子动力学同质模型.
主要成果:
- 克里奥奎诺在较低度下起到竞争性α1上腺受体对手的作用.
- 这种竞争的对抗性有助于降低血管收缩性.
- 分子动力学模拟证实了克里奥基诺尔与α1受体的正经位点的稳定结合.
结论:
- 克里奥基诺在血管收缩性上表现出双重作用机制:高度的非竞争性对抗作用和低度的竞争性α1 adrenoceptor对抗作用.
- α1上腺受体的竞争性对抗是一种新的机制,有助于克里奥基诺的血管扩张作用.
- 了解这些机制可能有助于开发用于各种疾病的基于clioquinol的治疗方法.
相关概念视频
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
879
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
879
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
809
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
809
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
448
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
448
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
607
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
607
01:24Cholinergic Antagonists: Pharmacokinetics
440
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
440
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
635
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
635